

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/73279 A1

(51) International Patent Classification⁷: C07D 239/42, 239/48, 239/34, 239/38, 239/28, 401/04, A61K 31/505, A61P 29/00

(74) Agent: POPPE, Regina; Grenzacherstrasse 124, CH-4070 Basel (CH).

(21) International Application Number: PCT/EP00/04701

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 24 May 2000 (24.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99110483.7 31 May 1999 (31.05.1999) EP

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; 124, Grenzacherstrasse, CH-4070 Basel (CH).


(72) Inventors: BOES, Michael; 3550 Jeanne Mance, App. E 1906, Montreal, Quebec H2X 3P7 (CA). GALLEY, Guido; Katzenbuckeweg 14, D-79618 Rheinfelden (DE). GODEL, Thierry; 7, Mittlere Strasse, CH-4056 Basel (CH). HOFFMANN, Torsten; 71, Muttenzerstrasse, CH-4127 Birsfelden (CH). HUNKELER, Walter; 32, Im Stigler, CH-4312 Magden (CH). SCHNIDER, Patrick; 7, Stallenrain, CH-4104 Oberwil (CH). STADLER, Heinz; 37, Waldhofstrasse, CH-4310 Rheinfelden (CH).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 4-PHENYL-PYRIMIDINE DERIVATIVES




WO 00/73279 A1

(57) Abstract: The invention relates to compounds of formula (I) wherein R¹ is hydrogen or halogen; R² is hydrogen, halogen, lower alkyl or lower alkoxy; R¹ and R² may be together with the two carbon atoms -CH=CH-CH=CH-; R³ is halogen, trifluoromethyl, lower alkyl or lower alkoxy; R⁴/R^{4'} are independently from each other hydrogen or lower alkyl; R⁵ is lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, -(CH₂)_n-piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, -(CH₂)_n-morpholinyl, -(CH₂)_n-piperidinyl, -(CH₂)_{n+1}-imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH₂)_{n+1}N(R⁴)₂, -(CH₂)_{n+1}N(R⁴)₂, -O-(CH₂)_{n+1}-morpholinyl, -O-(CH₂)_{n+1}-piperidinyl or -O-(CH₂)_{n+1}N(R⁴)₂, wherein R⁴ is hydrogen or lower alkyl; and n is 0 - 2; X is -C(O)N(R⁴)- or -N(R⁴)C(O)-; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that the compounds have a good affinity to the NK-1 receptor and may therefore be used for the treatment of diseases related to this receptor.

4-Phenyl-pyrimidine derivatives

The present invention relates to compounds of the general formula



wherein

- R^1 is hydrogen or halogen;
- 5 R^2 is hydrogen, halogen, lower alkyl or lower alkoxy;
- R^1 and R^2 may be together with the two carbon ring atoms $-CH=CH-CH=CH-$;
- R^3 is halogen, trifluoromethyl, lower alkyl or lower alkoxy;
- R^4/R^4' are independently from each other hydrogen or lower alkyl;
- 10 R^5 is lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, $-(CH_2)_n$ -piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, $-(CH_2)_n$ -morpholinyl, $-(CH_2)_n$ -piperidinyl, $-(CH_2)_{n+1}$ -imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, $-NH-(CH_2)_{n+1}N(R^4'')_2$, $-(CH_2)_{n+1}N(R^4'')_2$, $-O-(CH_2)_{n+1}$ -morpholinyl, $-O-(CH_2)_{n+1}$ -piperidinyl or $-O-(CH_2)_{n+1}N(R^4'')_2$, wherein R^4'' is hydrogen or lower alkyl; and
- 15 n is 0 - 2;
- X is $-C(O)N(R^4'')-$ or $-N(R^4'')C(O)-$;

and to pharmaceutically acceptable acid addition salts thereof.

The compounds of formula I and their salts are characterized by valuable therapeutic properties. It has been surprisingly found that the compounds of the present invention are

Pop/25.02.2000

antagonists of the Neurokinin 1 (NK-1, substance P) receptor. Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue.

- 5 The receptor for substance P is a member of the superfamily of G protein-coupled receptors.

The neuropeptide receptors for substance P (NK-1) are widely distributed throughout the mammalian nervous system (especially brain and spinal ganglia), the circulatory system and peripheral tissues (especially the duodenum and jejunum) and are 10 involved in regulating a number of diverse biological processes.

The central and peripheral actions of the mammalian tachykinin substance P have been associated with numerous inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's disease 15 (Neurosci. Res., 1996, 7, 187-214), anxiety (Can. J. Phys., 1997, 75, 612-621) and depression (Science, 1998, 281, 1640-1645).

Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic 20 inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases reviewed in "Tachykinin Receptor and Tachykinin Receptor Antagonists", J. Auton. Pharmacol., 13, 23-93, 1993.

25 Furthermore, Neurokinin 1 receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinin, in particular substance P. Examples of conditions in which substance P has been implicated include disorders of the central nervous system such as anxiety, depression and psychosis (WO 95/16679, WO 95/18124 and WO 95/23798).

- 30 The neurokinin-1 receptor antagonists are further useful for the treatment of motion sickness and for treatment induced vomiting.

In addition, in The New England Journal of Medicine, Vol. 340, No. 3 190-195, 1999 has been described the reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist.

Furthermore, US 5,972,938 describes a method for treating a psychoimmunologic or a psychosomatic disorder by administration of a tachykinin receptor, such as NK-1 receptor antagonist.

Objects of the present invention are the compounds of formula I and pharmaceutically acceptable salts thereof, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture as well as the use of the above-mentioned compounds in the control or prevention of illnesses, especially of illnesses and disorders of the kind referred to earlier or in the manufacture of corresponding medicaments.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders or emesis by the administration of NK-1 receptor antagonists. A major depressive episode has been defined as being a period of at least two weeks during which, for most of the day and nearly every day, there is either depressed mood or the loss of interest or pleasure in all, or nearly all activities.

The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination. As used herein, the term "lower alkyl" denotes a straight- or branched-chain alkyl group containing from 1-7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like.

Preferred lower alkyl groups are groups with 1-4 carbon atoms.

The term "lower alkoxy" denotes a group wherein the alkyl residues are as defined above, and which is attached via an oxygen atom.

The term "halogen" denotes chlorine, iodine, fluorine and bromine.

The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

Exemplary preferred are compounds, in which X is $-C(O)N(R^4)-$, wherein R^4 is methyl, and R^5 is piperazinyl, optionally substituted by one or two methyl groups, for example the following compounds:

4-(2-bromo-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,

- (3R,5S)-4-(2-bromo-phenyl)-2-(3,5-dimethyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 4-(2-bromo-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 5 4-(2-chloro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- (3R,5S)-4-(2-chloro-phenyl)-2-(3,5-dimethyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 4-(2-chloro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 10 2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 15 2-piperazin-1-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 4-(2-methoxy-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(2-methoxy-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 20 4-(2-methoxy-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 4-(4-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 25 4-(2-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(2-fluoro-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 4-(4-fluor-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 30 4-(4-fluoro-2-methyl-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
- 35 4-(4-fluor-2-methyl-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,

- 2-(4-methyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
(3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
5 4-naphthalen-1-yl-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-chloro-4-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and
4-(2-chloro-4-fluoro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-
10 trifluoromethyl-benzyl)-methyl-amide

Further preferred are compounds, in which X is $-C(O)N(R^4)-$, wherein R^4 is methyl and R^5 is morpholinyl or $-O(CH_2)_2$ -morpholinyl.

Examples of such compounds are:

- 4-(2-bromo-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
15 4-(2-chloro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-chloro-phenyl)-2-(2-morpholin-4-yl-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
20 2-morpholin-4-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-methoxy-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(4-fluoro-2-methyl-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-
25 trifluoromethyl-benzyl)-methyl-amide,
2-morpholin-4-yl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and
4-(2-chloro-4-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-
30 trifluoromethyl-benzyl)-methyl-amide

- Preferred are further compounds, in which X is $-C(O)N(R^4)-$, R^4 is methyl and R^5 is $-NH(CH_2)_2N(CH_3)_2$, $-O(CH_2)_2N(CH_3)_2$ or $-O(CH_2)_3N(CH_3)_2$, for example the following compounds:
4-(2-chloro-phenyl)-2-(2-dimethylamino-ethylamino)-pyrimidine-5-carboxylic acid (3,5-
35 bis-trifluoromethyl-benzyl)-methyl-amide


- 4-(2-chloro-phenyl)-2-(2-dimethylamino-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
 4-(2-chloro-phenyl)-2-(3-dimethylamino-propoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
 5 2-(2-dimethylamino-ethoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide or
 2-(3-dimethylamino-propoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide.

10 Preferred are further compounds, in which X is $-N(R^{4''})C(O)-$, $R^{4''}$ is methyl and R^5 is morpholinyl or piperazinyl, optionally substituted by lower alkyl, for example the following compounds:


- 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidin-5-yl]-isobutyramide and
 15 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(2-morpholin-4-yl-4-o-tolyl-pyrimidin-5-yl)-isobutyramide.

The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises

20 a) reacting a compound of formula




with a compound of formula



to a compound of formula


- 7 -



wherein R¹-R⁵ and n have the significances given above,


or

- b) reacting a compound of formula




5

with a compound of formula



to give a compound of formula



10

wherein R¹-R⁵ and n have the significances given above, or

- c) modifying one or more substituents R¹-R⁵ within the definitions given above, and

if desired, converting the compound obtained into a pharmaceutically acceptable acid addition salt.

In accordance with process variant a) to a mixture of a compound of formula II, for example methyl-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidin-3-yl]amine, and a compound of formula III, for example 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride in dichloromethane, DIPEA (N-ethyldiisopropyl-amine) is added and
5 the mixture is stirred at temperatures between 35-40°C. The desired compound of formula I-1 is obtained after purification in good yields.

Process variant b) describes the reaction of a compound of formula IV with a compound of formula V to a compound of formula I-2. The reaction is carried out in conventional manner, for example in a solvent, such as dichloromethane in presence of
10 triethylamine, EDCI (N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride) and HOBT (1-hydroxy-benzotriazole). The mixture is stirred for about 12 hours at 20°.


The salt formation is effected at room temperature in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids came into consideration.
15 Hydrochlorides, hydrobromides, sulphates, nitrates, citrates, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.

The following schemes 1-6 describe the processes for preparation of compounds of formula I in more detail. The starting materials of formulae V, VIII, X, XIV and XVIII are known compounds and may be prepared according to methods known in the art.

20 In the schemes the following abbreviations have been used:


THF	tetrahydrofuran
DIPEA	N-ethyldiisopropyl-amine
HOBT	1-hydroxy-benzotriazole
EDCI	N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride
m-CPBA	m-chloroperbenzoic acid
DPPA	diphenylphosphorylazide
DMF	dimethylformamide
NEt ₃	triethylamine

Scheme 1



The substituents are given above.


Scheme 2



$\text{Y} = \text{halogen}$
 $\text{R}^{4''} = \text{lower alkyl}$


The substituents are given above.

Scheme 3



R' is lower alkyl and Y is halogen. A is an amine group such as $-\text{N}(\text{R}^4)_2$, piperazinyl, morpholinyl, piperidinyl or imidazolyl. The remaining substituents are given above.


Scheme 4



The definition of substituents is given above.

- 11 -


Scheme 5



This reaction type is described in Bioorg. & Med. Chem., Vol.5, No 2, pp437-444, 1997

R^1-R^4 and n have the significances given above, B is lower alkoxy, $-\text{O}-(\text{CH}_2)_{n+1}\text{N}(\text{R}^4)_2$, $-\text{O}-(\text{CH}_2)_{n+1}$ -morpholinyl or $-\text{O}-(\text{CH}_2)_{n+1}$ -piperidinyl and A' is an amine group such as $-\text{N}(\text{R}^4)_2$, piperazinyl, optionally substituted, morpholinyl, piperidinyl, imidazolyl, 5 benzylamine or $-\text{NH}-(\text{CH}_2)_{n+1}\text{N}(\text{R}^4)_2$.

Scheme 6



R^1-R^4 and n have the significances given above, B is lower alkoxy, $-\text{O}-(\text{CH}_2)_{n+1}\text{N}(\text{R}^4)_2$, $-\text{O}-(\text{CH}_2)_{n+1}$ -morpholinyl or $-\text{O}-(\text{CH}_2)_{n+1}$ -piperidinyl and A' is an amine group such as $-\text{N}(\text{R}^4)_2$, piperazinyl, optionally substituted, morpholinyl, piperidinyl, imidazolyl, 5 benzylamine or $-\text{NH}-(\text{CH}_2)_{n+1}\text{N}(\text{R}^4)_2$.

As mentioned earlier, the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. It has

been found that the compounds of the present invention are antagonists of the Neurokinin 1 (NK-1, substance P) receptor.

The compounds were investigated in accordance with the tests given hereinafter.

The affinity of test compounds for the NK₁ receptor was evaluated at human NK₁ receptors
 5 in CHO cells infected with the human NK₁ receptor (using the Semliki virus expression system) and radiolabelled with [³H]substance P (final concentration 0.6 nM). Binding assays were performed in HEPES buffer (50 mM, pH 7.4) containing BSA (0.04 %) leupeptin (8 µg / ml), MnCl₂ (3mM) and phosphoramidon (2 µM). Binding assays
 10 consisted of 250 µl of membrane suspension (1.25x10⁵ cells / assay tube), 0.125 µl of buffer of displacing agent and 125 µl of [³H]substance P. Displacement curves were determined with at least seven concentrations of the compound. The assay tubes were incubated for 60 min at room temperature after which time the tube contents were rapidly filtered under vacuum through GF/C filters presoaked for 60 min with PEI (0.3%) with 2 x 2 ml washed of HEPES buffer (50 mM, pH 7.4). The radioactivity retained on the filters was measured
 15 by scintillation counting. All assays were performed in triplicate in at least 2 separate experiments.

The affinity to the NK-1 receptor, given as pKi, is in the scope of 8.00-9.20 for the preferred compounds. Examples of such compounds are

4-(2-Chloro-phenyl)-2-(2-dimethylamino-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide	8.45
4-(2-Chloro-phenyl)-2-(3-dimethylamino-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide	8.11
4-(2-Chloro-phenyl)-2-(3-dimethylamino-propoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide	8.76
4-(4-Fluor-2-methyl-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide	9.14
2-(4-Methyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide	8.54

20 The compounds of formula I as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated

tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I and their pharmaceutically usable acid addition salts
5 can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragées and hard gelatine capsules.

Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-
10 solid and liquid polyols etc.

Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.

Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.

15 Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.

Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still
20 other therapeutically valuable substances.

The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.

25 The following Examples illustrate the present invention without limiting it. All temperatures are given in degrees Celsius.

Example 1

2-Methyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

30 a) 2-Methyl-4-phenyl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide

To a solution of 0.50 g (2.33 mmol) 2-methyl-4-phenyl-pyrimidine-5-carboxylic acid 0.65 ml (4.47 mmol) triethylamin, 0.44 g (2.33 mmol) 1-hydroxy-benzotriazol and 0.44 g (2.33 mmol) N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in 40 ml CH₂Cl₂ 0.68 g (2.8 mmol) 3,5-bis-trifluormethyl-benzylamin were added. The reaction mixture
5 was stirred for 16 hrs. The reaction mixture was diluted with 20 ml CH₂Cl₂, washed with 50 ml 0.5N HCl and 50 ml H₂O. The aqueous layers were backextracted with 50 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, ethyl acetate) to give 0.80 g (78%) 2-methyl-4-phenyl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide as a
10 colorless solid, m.p. 188.5-189.5°.

b) 2-Methyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.67 g (1.52 mmol) methyl-4-phenyl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide in 10 ml N,N-dimethylformamide 0.08 g (1.98 mmol)
15 sodiumhydride (60% dispersion in mineral oil) was added and the reaction mixture stirred for 1 hr. After the addition of 0.15 ml (2.4 mmol) methyl iodide at 0°, the reaction mixture was stirred for 3 hrs. at RT. The reaction mixture was distributed between 50 ml H₂O, 50 ml brine and 50 ml CH₂Cl₂. The phases were separated, the aqueous layer washed twice with 50 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and
20 evaporated. The residue was purified by chromatography (SiO₂, éthyl acetate/hexane 4:1) to give 0.50 g (72 %) 2-methyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (EI): 453 (M⁺).

Example 2

2-Methyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-dichloro-benzyl)-methyl-amide

25 In an analogous manner to that described in Example 1 a) there was obtained from 2-methyl-4-phenyl-pyrimidine-5-carboxylic acid and 3,5-dichlorobenzylamine 2-methyl-4-phenyl-pyrimidine-5-carboxylic acid 3,5-dichloro-benzylamide as a colorless solid, m.p. 194-195°, which was methylated as described in Example 1 b) to give 2-methyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-dichloro-benzyl)-methyl-amide as a colorless oil, MS
30 (EI): 385 (M⁺).

Example 3

4-(2-Bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

a) 2-(2-Bromo-benzoyl)-3-dimethylamino-acrylic acid ethyl ester

To a solution of 25.9 g (95.5 mmol) 3-(2-bromo-phenyl)-3-oxo-propionic acid ethyl ester in 200 ml toluene 18.21 g (152 mmol) N,N-dimethylformamide-dimethylacetal dissolved in 100 ml toluene was added during 1 hr. The reaction mixture was stirred for 1.5 hrs. at 5 100°. The solvent was evaporated and the residue purified by chromatography (SiO₂, CH₂Cl₂/MeOH 40:1) to give 25 g (80%) 2-(2-bromo-benzoyl)-3-dimethylamino-acrylic acid ethyl ester as a pale brown solid.

b) 4-(2-Bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid ethyl ester

To a fresh prepared solution of sodiummethanolate (prepared from 0.77 g (33.7 mmol) Na 10 in 100 ml Ethanol) 3.18 g (33.7 mmol) acetamidinhydrochloride was added. After 10 Min. a solution of 10.0 g (30.6 mmol) 2-(2-bromo-benzoyl)-3-dimethylamino-acrylic acid ethyl ester in 120 ml ethanol was added and the reaction mixture heated for 16 hrs. at 80°. The solvent was evaporated, the residue distributed between 100 ml H₂O and 100 ml CH₂Cl₂. The aqueous phase was extracted twice with 100 ml CH₂Cl₂. The combined organic layers 15 were dried (MgSO₄), filtrated and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH 40:1) to give 8.3 g (84%) 4-(2-bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid ethyl ester as a pale brown oil.

c) 4-(2-Bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid

To a solution of 8.3 g (25.8 mmol) 4-(2-bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic 20 acid ethyl ester in 10 ml ethanol 1.55 g (38.6 mmol) NaOH in 20 ml H₂O was added. After stirring for 1 hr., the reaction mixture was washed with 100 ml diethylether. The pH of the aqueous phase was adjusted to 1 with 25% HCl and than extracted twice with 200 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtrated and evaporated to give 25 7.0 g (92%) 4-(2-bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid as a pale yellow foam.

d) 4-(2-Bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethylbenzyl)-methyl-amide

To a solution of 0.5 g (1.71 mmol) 4-(2-bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid, 0.47 ml (3.41 mmol) triethylamin, 0.26 g (1.71 mmol) 1-hydroxy-benzotriazol and 30 0.32 g (1.71 mmol) N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in 40 ml CH₂Cl₂ 0.52 g (2.0 mmol) (3,5-bis-trifluoromethyl-benzyl)-methyl-amine were added. The reaction mixture was stirred for 16 hrs. The reaction mixture was diluted with

20 ml CH₂Cl₂, washed with 50 ml 0.5N HCl and 50 ml H₂O. The aqueous layers were backextracted with 50 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, ethyl acetate) to give 0.7 g (77%) 4-(2-bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 121.5-122.5°.

Example 4

4-(2-Bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide

To a solution of 0.5 g (1.71 mmol) 4-(2-bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid, 0.47 ml (3.41 mmol) triethylamin, 0.26 g (1.71 mmol) 1-hydroxy-benzotriazol and 0.32 g (1.71 mmol) N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in 40 ml CH₂Cl₂ 0.49 g (2.05 mmol) 3,5-bis-trifluoromethylbenzylamin was added. The reaction mixture was stirred for 16 hrs. The reaction mixture was diluted with 20 ml CH₂Cl₂, washed with 50 ml 0.5N HCl and 50 ml H₂O. The aqueous layers were backextracted with 50 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH) to give 0.4 g (45 %) 4-(2-bromo-phenyl)-2-methyl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide as a colorless solid, m.p. 137.5-138.5°.

Example 5

20 2,4-Diphenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide
In an analogous manner to that described in Example 1 a) there was obtained from 2,4-diphenyl-pyrimidine-5-carboxylic acid and 3,5-bis-trifluoromethyl-benzylamine 2,4-diphenyl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide as a colorless solid, m.p. > 220°, which was methylated as described in Example 1 b) to give
25 2,4-diphenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 516.2 (M+H⁺).

Example 6

2,4-Diphenyl-pyrimidine-5-carboxylic acid (3,5-dichlorobenzyl)-methyl-amide

In an analogous manner to that described in Example 1 a) there was obtained from 2,4-diphenyl-pyrimidine-5-carboxylic acid and 3,5-dichlorobenzylamine 2,4-diphenyl-pyrimidine-5-carboxylic acid 3,5-bis-chloro-benzylamide as a colorless solid, m.p. > 220°, which was methylated as described in Example 1 b) to give 2,4-diphenyl-pyrimidine-5-carboxylic acid (3,5-dichlorobenzyl)-methyl-amide as a colorless oil, MS (ISP): 448 (M+H⁺).

Example 7**4-Phenyl-2-propyl-pyrimidine-5-carboxylic acid (3,5-dichloro-benzyl)-methyl-amide**

In an analogous manner to that described in Example 1 a) there was obtained from 4-phenyl-2-propyl-pyrimidine-5-carboxylic acid and 3,5-dichlorobenzylamine

- 5 4-phenyl-2-propyl-pyrimidine-5-carboxylic acid 3,5-dichloro-benzylamide as a colorless solid, m.p. 183°, which was methylated as described in Example 1 b) to give 4-phenyl-2-propyl-pyrimidine-5-carboxylic acid (3,5-dichloro-benzyl)-methyl-amide as a colorless oil, MS (EI): 413 (M⁺).

The 4-phenyl-2-propyl-pyrimidine-5-carboxylic acid used as the starting substance was
10 obtained as follows:

In an analogous manner to that described in example 3b) starting from 2-benzoyl-3-dimethylamino-acrylic acid ethyl ester and butyramidine hydrochloride, followed by saponification as described in example 3c) there was obtained 4-phenyl-2-propyl-pyrimidine-5-carboxylic acid.

15

Example 8**4-Phenyl-2-propyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 1 a) there was obtained from 4-phenyl-2-propyl-pyrimidine-5-carboxylic acid and 3,5-bis-trifluoromethyl-benzylamine 4-

- 20 4-phenyl-2-propyl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide as a colorless solid, m.p. 194°-195°, which was methylated as described in Example 1 b) to give 4-phenyl-2-propyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 482.3 (M+H⁺).

25

Example 9**4-Phenyl-2-pyridin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 3 d) there was obtained from 4-phenyl-2-pyridin-4-yl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-

- 30 methyl-amine 4-phenyl-2-pyridin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 143°-144°.

The 4-phenyl-2-pyridin-4-yl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

In an analogous manner to that described in example 3 b) starting from 2-benzoyl-3-dimethylamino-acrylic acid ethyl ester and isonicotinamide hydrochloride, followed by saponification as described in example 3c) there was obtained 4-phenyl-2-pyridin-4-yl-pyrimidine-5-carboxylic acid.

Example 10

4-Phenyl-[2,2']bipyrimidinyl-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 3 d) there was obtained from 4-phenyl-[2,2']bipyrimidinyl-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-

10 methyl-amine 4-phenyl-[2,2']bipyrimidinyl-5-carboxylic acid (3,5-bis-trifluoromethylbenzyl)-methyl-amide as a colorless solid, m.p. 172°-173°.

The 4-phenyl-[2,2']bipyrimidinyl-5-carboxylic acid used as the starting substance was obtained as follows:

In an analogous manner to that described in example 3 b) starting from 2-benzoyl-3-dimethylamino-acrylic acid ethyl ester and pyrimidine-2-carboxamidine hydrochloride, followed by saponification as described in example 3c) there was obtained 4-phenyl-[2,2']bipyrimidinyl-5-carboxylic acid.

Example 11

2-Methyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-
benzylamide

In an analogous manner to that described in Example 1 a) there was obtained from 2-methyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid and 3,5-bis-(trifluoromethyl)-benzylamine 2-methyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide as a colorless solid, m.p. 146.7°-146.9°.

25 The used 2-methyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid as the starting substance was obtained as follows:

In an analogous manner to that described in example 3 a) – 3 c) starting from 3-naphthalen-1-yl-3-oxo-propionic acid ethyl ester and N,N-dimethylformamide-dimethylacetal there was obtained 2-methyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid.

Example 12

2-Methyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 1 b) there was obtained from 2-methyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide and methyliodid 2-methyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 164.9°-165.2°.

5

Example 13

4-(2-Methoxy-phenyl)-2-methyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 3 d) there was obtained from 4-(2-

- 10 methoxy-phenyl)-2-methyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 4-(2-methoxy-phenyl)-2-methyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 140°-141°.

The used 4-(2-methoxy-phenyl)-2-methyl-pyrimidine-5-carboxylic acid as the starting substance was obtained as follows:

- 15 In an analogous manner to that described in example 3 a) – 3 c) starting from 3-(2-methoxy-phenyl)-3-oxo-propionic acid ethyl ester and N,N-dimethylformamide-dimethylacetal there was obtained 4-(2-methoxy-phenyl)-2-methyl-pyrimidine-5-carboxylic acid.

Example 14

- 20 **2-Methylsulfanyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

To a solution of 3 g (12.18 mmol) 2-methylsulfanyl-4-phenyl-pyrimidine-5-carboxylic acid, 3.32 ml (24.36 mmol) triethylamin, 1.84 g (12.18 mmol) 1-hydroxybenzotriazol and 2.33 g (12.81 mmol) N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in

- 25 170 ml CH₂Cl₂ 3.76 g (14.62 mmol) (3,5-bis-trifluoromethyl-benzyl)-methyl-amine were added. The reaction mixture was stirred for 16 hrs. The reaction mixture was diluted with 100 ml CH₂Cl₂, washed with 100 ml 0.5N HCl and 100 ml H₂O. The aqueous layers were backextracted with 100 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/ethyl acetate) to give 4.15 g (67 %) 2-methylsulfanyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 119.1-119.8°.

Example 15

2-Methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 4.15 g (85.5 mmol) 2-methylsulfanyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 170 ml CH₂Cl₂ 5.27 g (21.4 mmol) 3-chloroperbenzoic acid (70%) was added at 5° and the reaction mixture stirred for 3 hrs. at RT. After addition of 150 ml sat. NaHCO₃-solution, the layers were separated, the 5 organic phase washed with sat. NaHCO₃-solution, dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/methanol 40:1) to give 4.20 g (95 %) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, MS (EI): 517 (M⁺).

Example 16

- 10 2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.5 g (0.97 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml dioxan 0.27 ml (2.42 mmol) 1-methylpiperazine was added. The reaction mixture was stirred for 16 hrs. After 15 evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/methanol 9:1) to give 0.4 g (77 %) 2-(4-methyl-piperazin-1-yl)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless 20 oil, MS (ISP): 538.3 (M+H⁺).

Example 17

- 2-Benzylamino-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.4 g (0.77 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml dioxan 0.21 ml (1.923 mmol) benzylamin were added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, 25 CH₂Cl₂/methanol 40:1) to give 0.2 g (47 %) 2-benzylamino-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, 117.2-118.1°.

Example 18

2-Morpholin-4-yl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.4 g (0.77 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml dioxan 0.17 ml (1.93 mmol) morpholin was added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/methanol 40:1) to give 0.21 g (52 %) 2-morpholin-4-yl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, 168.1-168.4°.

Example 19

4-Phenyl-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.5 g (0.96 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml dioxan 0.208 g (2.15 mmol) piperazin was added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/methanol 40:1) to give 0.42 g (83 %) 4-phenyl-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 524.1 (M+H⁺).

Example 20

(3R,5S)-2-(3,5-Dimethyl-piperazin-1-yl)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.5 g (0.96 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml dioxan 0.276 g (2.15 mmol) cis-2,6-dimethyl-piperazin was added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/methanol 40:1) to give 0.51 g (96 %) (3R,5S)-2-(3,5-dimethyl-piperazin-1-

yl)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 552.1 (M+H⁺).

Example 21

- 2-(2-Dimethylamino-ethylamino)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide
- To a solution of 0.4 g (0.77 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml dioxan 0.211 ml (1.93 mmol) 2-dimethylaminoethylamin was added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/methanol/NH₄OH 140:10:1) to give 0.22 g (54 %) 2-(2-dimethylamino-ethylamino)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 109.5-110.3°.

Example 22

- 4-Phenyl-2-piperidin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide
- To a solution of 0.5 g (0.96 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml dioxan 0.183 g (2.15 mmol) piperidin was added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/ethyl acetate 20:1) to give 0.48 g (95 %) 4-phenyl-2-piperidin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a waxy pale yellow solid, MS (ISP): 523.2 (M+H⁺).

Example 23

- 2-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide
- To a solution of 0.5 g (0.96 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml dioxan 0.28 g (2.15 mmol) N-(2-hydroxyethyl)piperazin was added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers

dried (MgSO_4), filtered and evaporated. The residue was purified by chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 6:1) to give 0.43 g (78 %) 2-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a waxy pale yellow solid, MS (ISP): 568.2 ($M+\text{H}^+$).

5

Example 24

2-(2-Morpholin-4-yl-ethoxy)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.5 g (0.96 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 20 ml acetonitrile 0.15 g (1.16

10 mmol) N-(2-hydroxyethyl)morpholine and 1.57 g (4.83 mmol) Cs_2CO_3 were added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH_2Cl_2 and 50 ml H_2O . The aqueous layer was extracted with 50 ml CH_2Cl_2 , the combined organic layers dried (MgSO_4), filtered and evaporated. The residue was purified by chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 40:1) to give 0.39 g (68 %)

15 2-(2-morpholin-4-yl-ethoxy)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a pale yellow oil, MS (ISP): 569.2 ($M+\text{H}^+$).

Example 25

4-Phenyl-2-(2-piperidin-1-yl-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

20 To a solution of 0.5 g (0.96 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 20 ml acetonitrile 0.15 g (1.16 mmol) N-(2-hydroxyethyl)piperidin and 1.57 g (4.83 mmol) Cs_2CO_3 were added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH_2Cl_2 and 50 ml H_2O . The aqueous layer was extracted with

25 50 ml CH_2Cl_2 , the combined organic layers dried (MgSO_4), filtered and evaporated. The residue was purified by chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 200:10:1) to give 0.47 g (85 %) 4-phenyl-2-(2-piperidin-1-yl-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a pale yellow oil, MS (ISP): 567.2 ($M+\text{H}^+$).

Example 26

30 **2-(2-Dimethylamino-ethoxy)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

To a solution of 0.5 g (0.96 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 20 ml acetonitrile 0.10 g (1.16 mmol) 2-dimethylamino-ethanol and 1.57 g (4.83 mmol) Cs_2CO_3 were added. The

- reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 110:10:1) to give
- 5 0.43 g (82 %) 2-(2-dimethylamino-ethoxy)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a pale yellow oil, MS (ISP): 527.2 (M+H⁺).

Example 27

2-(3-Dimethylamino-propoxy)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 10 To a solution of 0.5 g (0.96 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 20 ml acetonitrile 0.14 ml (1.16 mmol) 2-dimethylamino-propanol and 1.57 g (4.83 mmol) Cs₂CO₃ were added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with
- 15 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 110:10:1) to give 0.50 g (95 %) 2-(3-dimethylamino-propoxy)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a pale yellow oil, MS (ISP): 541.2 (M+H⁺).

Example 28

- 20 **2-Methoxy-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**
To a suspension of 0.4 g (0.77 mmol) 2-methylsulfonyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 10 ml methanol 0.10 g (1.93 mmol) sodiummethanolat (95%) was added. The reaction mixture was stirred for 16
- 25 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH 40:1) to give 0.23 g (63 %) 2-methoxy-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless
- 30 solid, m.p. 101.2-102°.

Example 29

2-Carbamoylmethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 3 d) there was obtained from 2-carbamoylmethyl-4-phenyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 2-carbamoylmethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 161°-163°.

- 5 The 2-carbamoylmethyl-4-phenyl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

In an analogous manner to that described in example 3b) starting from 2-benzoyl-3-dimethylamino-acrylic acid ethyl ester and malonamidine hydrochloride, followed by saponification as described in Example 3c) there was obtained 2-carbamoylmethyl-4-
10 phenyl-pyrimidine-5-carboxylic acid.

Example 30

2-Cyanomethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.50 g (1.01 mmol) in 2-carbamoylmethyl-4-phenyl-pyrimidine-5-
15 carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 0.17 ml pyridine in 10 ml dioxane 0.15 ml (1.06 mmol) trifluoracetic anhydride were added and the resulting reaction mixture was stirred for 1 hr. at 50°. The reaction mixture was poured on Ice/H₂O and extracted three times with 50 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂,
20 CH₂Cl₂/MeOH 30:1) to give 0.25 g (51%) 2-cyanomethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 114-116°.

Example 31

2-Hydroxymethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 3 d) there was obtained from 2-hydroxymethyl-4-phenyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 2-hydroxymethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (EI): 469 (M⁺).
30 The used 2-hydroxymethyl-4-phenyl-pyrimidine-5-carboxylic acid as the starting substance was obtained as follows:

In an analogous manner to that described in example 3 b) starting from 2-benzoyl-3-dimethylamino-acrylic acid ethyl ester and 2-hydroxy-acetamidine hydrochloride followed

by saponification as described in Example 3c), there was obtained 2-hydroxymethyl-4-phenyl-pyrimidine-5-carboxylic acid.

Example 32

2-Dimethylaminomethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

a) Methanesulfonic acid 5-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-4-phenyl-pyrimidin-2-ylmethyl ester

To a solution of 2.64 g (5.62 mmol) 2-hydroxymethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1.17 ml (8.44 mmol) triethylamine in 30 ml CH₂Cl₂ 0.479 ml (6.19 mmol) methansulfonylchloride were added at 0°. The reaction mixture was stirred for 16 hrs. The reaction mixture was poured on sat. NaHCO₃- solution and extracted three times with 50 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/ethyl acetate 8:1) to give 2.30 g (74 %) methanesulfonic acid 5-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-4-phenyl-pyrimidin-2-ylmethyl ester as a colorless viscous oil, MS (ISP): 548.1 (M+H⁺).

b) 2-Dimethylaminomethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.40 g (0.73 mmol) methanesulfonic acid 5-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-4-phenyl-pyrimidin-2-ylmethyl ester in 5 ml CH₂Cl₂ 1 ml 5.6 M dimethylamin-solution in ethanol were added. The reaction mixture was stirred for 16 hrs. at RT. The reaction mixture was poured into H₂O and extracted three times with 50 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH 20:1) to give 0.33 g (90 %) 2-dimethylaminomethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 497.2 (M+H⁺).

Example 33

2-Morpholin-4-ylmethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

30 To a solution of 0.40 g (0.73 mmol) methanesulfonic acid 5-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-4-phenyl-pyrimidin-2-ylmethyl ester in 5 ml CH₂Cl₂ 0.095 ml (1.10 mmol) morpholine were added. The reaction mixture was stirred for 16 hrs. at RT. The reaction mixture was poured into H₂O and extracted three times with 50 ml CH₂Cl₂.

The combined organic layers were dried ($MgSO_4$), filtered and evaporated. The residue was purified by chromatography (SiO_2 , $CH_2Cl_2/MeOH$ 10:1) to give 0.33 g (88 %) 2-morpholin-4-ylmethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethylbenzyl)-methyl-amide as a pale yellow waxy solid, MS (ISP): 539.3 ($M+H^+$).

5

Example 34

2-(4-Methyl-piperazin-1-ylmethyl)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.40 g (0.73 mmol) methanesulfonic acid 5-[(3,5-bis-trifluoromethylbenzyl)-methyl-carbamoyl]-4-phenyl-pyrimidin-2-ylmethyl ester in 5 ml CH_2Cl_2 0.12 ml (1.1 mmol) N-methylpiperazine were added. The reaction mixture was stirred for 16 hrs. at RT and then poured into H_2O and extracted three times with 50 ml CH_2Cl_2 . The combined organic layers were dried ($MgSO_4$), filtered and evaporated. The residue was purified by chromatography (SiO_2 , $CH_2Cl_2/MeOH$ 10:1) to give 0.31 g (77 %) 2-(4-methyl-piperazin-1-ylmethyl)-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a pale yellow waxy solid, MS (ISP): 552.2 ($M+H^+$).

Example 35

4-Phenyl-2-piperidin-1-ylmethyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.40 g (0.73 mmol) methanesulfonic acid 5-[(3,5-bis-trifluoromethylbenzyl)-methyl-carbamoyl]-4-phenyl-pyrimidin-2-ylmethyl ester in 5 ml CH_2Cl_2 added 0.11 ml (1.1 mmol) piperidine were added. The reaction mixture was stirred for 16 hrs. at RT and then poured into H_2O and extracted three times with 50 ml CH_2Cl_2 . The combined organic layers were dried ($MgSO_4$), filtered and evaporated. The residue was purified by chromatography (SiO_2 , $CH_2Cl_2/MeOH$ 10:1) to give 0.32 g (81 %) 4-phenyl-2-piperidin-1-ylmethyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a pale yellow waxy solid, MS (ISP): 537.2 ($M+H^+$).

Example 36

2-Imidazol-1-ylmethyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.40 g (0.73 mmol) methanesulfonic acid 5-[(3,5-bis-trifluoromethylbenzyl)-methyl-carbamoyl]-4-phenyl-pyrimidin-2-ylmethyl ester and 0.04 g (0.80 mmol) sodiummethanolate in 15 ml N,N-dimethylformamide 0.59 g (0.88 mmol) imidazole was added. The reaction mixture was stirred for 16 hrs. at RT. The reaction mixture was

evaporated and the residue distributed between H₂O and CH₂Cl₂. The aqueous layer was extracted twice with 50 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH 10:1) to give 0.24 g (63 %) 2-imidazol-1-ylmethyl-4-phenyl-pyrimidine-5-5 carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a pale yellow solid, MS (ISP): 520.2 (M+H⁺).

Example 37

4-(2-Bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

10 a) 4-(2-Bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester

To a suspension of 3.81 g (46.54 mmol) sodiumacetate and 6.47 g (23.27 mmol) S-methylisothiourea sulfate in 100 ml N,N-dimethylformamide a solution of 6.90 g (21.15 mmol) 2-(2-bromo-benzoyl)-3-dimethylamino-acrylic acid ethyl ester in 20 ml N,N-dimethylformamide was added at once and the resulting reaction mixture was stirred for 15 16 hrs. at 90°. The solvent was evaporated and the residue distributed between 100 ml CH₂Cl₂ and 100 ml H₂O. The aqueous phase was extracted twice with 100 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂) to give 5.20 g (69 %) 4-(2-bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester as a pale green oil.

20 b) 4-(2-Bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid

To a solution of 5.10 g (14.4 mmol) 4-(2-bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester in 10 ml ethanol 10ml 2N NaOH-solution were added. After stirring for 1 hr. 50 ml H₂O and 50 ml CH₂Cl₂ were added to the yellow solution. The pH of the aqueous phase was adjusted to 1 with 25% HCl, the phases separated and the aqueous phase extracted twice with 200 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtrated and evaporated to give 4.60 g (98%) 4-(2-bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid as a off-white solid.

c) 4-(2-Bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

30 To a solution of 2 g (6.15 mmol) 4-(2-bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid, 1.71 ml (12.3 mmol) triethylamin, 0.94 g (6.15 mmol) 1-hydroxybenzotriazol and 1.17 g (6.15 mmol) N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide in 70 ml CH₂Cl₂ 1.63 g (6.34 mmol) (3,5-bis-trifluoromethyl-benzyl)-

methyl-amine were added. The reaction mixture was stirred for 16 hrs. The reaction mixture was diluted with 50 ml CH₂Cl₂, washed with 50 ml 0.5N HCl and 50 ml H₂O. The aqueous layers were backextracted with 75 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography 5 (SiO₂, CH₂Cl₂/MeOH 40:1) to give 3.0 g (86 %) 4-(2-bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 566, 564 (M+H⁺).

Example 38

4-(2-Bromo-phenyl)-2-methanesulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-10 trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 15 there was obtained from 4-(2-bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 3-chloroperbenzoic acid 4-(2-bromo-phenyl)-2-methanesulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-15 amide as a white foam, MS (ISP): 598, 596 (M+H⁺).

Example 39

2-Amino-4-(2-bromo-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

To a solution of 0.42 g (0.7 mmol) 4-(2-bromo-phenyl)-2-methylsulfonyl-pyrimidine-5-20 carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 30 ml N,N-dimethylformamide a stream of NH₃ was introduced during 10 Min. The reaction solution was stirred for 4 hrs. The solvent was evaporated and the residue distributed between 20 ml CH₂Cl₂ and 20 ml H₂O. The aqueous phase was extracted twice with 30 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was 25 purified by chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 140:10:1) to give 0.29 g (77 %) 2-amino-4-(2-bromo-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 535.1, 533.1 (M+H⁺).

Example 40

4-(2-Bromo-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-30 trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 16 there was obtained from 4-(2-bromo-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazin 4-(2-bromo-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-

amide as a white foam, MS (ISP): 618.1, 616.1 ($M+H^+$), which was treated with fumaric acid in the usual way to give 4-(2-bromo-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 179-180°.

Example 41

(3R,5S)-4-(2-bromo-phenyl)-2-(3,5-dimethyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 20 there was obtained from 4-(2-bromo-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and cis-2,6-dimethyl-piperazin (3R,5S)-4-(2-bromo-phenyl)-2-(3,5-dimethyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 632.0, 630.0 ($M+H^+$).

Example 42

4-(2-Bromo-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 19 there was obtained from 4-(2-bromo-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and Piperazin 4-(2-bromo-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 603.9, 601.9 ($M+H^+$).

Example 43

4-(2-Bromo-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 18 there was obtained from 4-(2-bromo-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and morpholine 4-(2-bromo-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 605, 603 ($M+H^+$).

Example 44

30 4-(2-Chloro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 37 c) there was obtained from 4-(2-chloro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 4-(2-chloro-phenyl)-2-methylsulfanyl-pyrimidine-

5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 519 (M^+).

The 4-(2-chloro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

- 5 In an analogous manner to that described in Example 37 a), b) there was obtained from 2-(2-chloro-benzoyl)-3-dimethylamino-acrylic acid ethyl ester and S-methylisothiourea sulfate followed by saponification 4-(2-chloro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid as a white foam.

Example 45

- 10 4-(2-Chloro-phenyl)-2-methanesulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 15 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 3-chloroperbenzoic acid 4-(2-chloro-phenyl)-2-

- 15 methanesulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 552.0 ($M+H^+$).

Example 46

4-(2-Chloro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 20 In an analogous manner to that described in Example 16 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazin 4-(2-chloro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 572.1 ($M+H^+$), which was treated with fumaric acid in the usual way to give 4-(2-chloro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 174.8-175.8°.

Example 47

(3R,5S)-4-(2-Chloro-phenyl)-2-(3,5-dimethyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 30 In an analogous manner to that described in Example 20 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and cis-2,6-dimethylpiperazine (3R,5S)-4-(2-chloro-phenyl)-2-

(3,5-dimethyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 586.1 (M+H⁺).

Example 48

- 4-(2-Chloro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 19 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and piperazine 4-(2-chloro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 558.2 (M+H⁺), which was treated with fumaric acid in the usual way to give 4-(2-chloro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 123-126°.

Example 49

- 4-(2-Chloro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 18 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and morpholine 4-(2-chloro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 559.1 (M+H⁺).

Example 50

- 4-(2-Chloro-phenyl)-2-(2-dimethylamino-ethylamino)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 21 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 2-dimethylaminoethylamin 4-(2-chloro-phenyl)-2-(2-dimethylamino-ethylamino)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 560.2 (M+H⁺).

Example 51

- 4-(2-Chloro-phenyl)-2-(2-morpholin-4-yl-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 24 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and N-(2-hydroxyethyl)morpholine 4-(2-chloro-phenyl)-2-(2-

morpholin-4-yl-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 603.0 ($M+H^+$).

Example 52

- 4-(2-Chloro-phenyl)-2-(2-dimethylamino-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 26 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 2-dimethylamino-ethanol 4-(2-chloro-phenyl)-2-(2-dimethylamino-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 561.2 ($M+H^+$).

Example 53

- 4-(2-Chloro-phenyl)-2-(3-dimethylamino-propoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 27 there was obtained from 4-(2-chloro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 2-dimethylamino-propanol 4-(2-chloro-phenyl)-2-(3-dimethylamino-propoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 575.1 ($M+H^+$).

Example 54

- 2-Methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 37 c) there was obtained from 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 499 (M^+).

The used 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid as the starting substance was obtained as follows:

In an analogous manner to that described in Example 37 a), b) there was obtained from 2-(2-methyl-benzoyl)-3-dimethylamino-acrylic acid ethyl ester and S-methylisothiourea sulfate followed by saponification 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid as a white foam.

Example 55

2-Methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 15 there was obtained from

- 5 2-methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 3-chloroperbenzoic acid 2-methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 532.1 ($M+H^+$).

Example 56

- 10 **2-(4-Methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 16 there was obtained from 2-methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazin 2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 552.1 ($M+H^+$), which was treated with fumaric acid in the usual way to give 2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 151.5-152.5°.

Example 57

- 20 **(3R,5S)-2-(3,5-Dimethyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 20 there was obtained from 2-methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and cis-2,6-dimethylpiperazine (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 566.3 ($M+H^+$), which was treated with fumaric acid in the usual way to give (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:0.5), m.p. 203.5-204.5°.

Example 58

- 30 **2-Piperazin-1-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 19 there was obtained from 2-methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and piperazine 2-piperazin-1-yl-4-o-tolyl-pyrimidine-5-carboxylic acid

(3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 538.3 ($M+H^+$), which was treated with fumaric acid in the usual way to give 2-piperazin-1-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 149.5-151.5°.

5

Example 59

2-Morpholin-4-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 18 there was obtained from 2-methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and morpholin 2-morpholin-4-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 538 (M^+).

Example 60

2-(2-Dimethylamino-ethoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

15 In an analogous manner to that described in Example 26 there was obtained from 2-methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 2-dimethylamino-ethanol 2-(2-dimethylamino-ethoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 541.2 ($M+H^+$).

20

Example 61

2-(3-Dimethylamino-propoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 27 there was obtained from 2-methylsulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 2-dimethylamino-propanol 2-(3-dimethylamino-propoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 555.2 ($M+H^+$).

Example 62

4-(2-Methoxy-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

30 In an analogous manner to that described in Example 37 c) there was obtained from 4-(2-methoxy-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 4-(2-methoxy-phenyl)-2-methylsulfanyl-

pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 515 (M^+).

The 4-(2-methoxy-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

- 5 In an analogous manner to that described in Example 37 a), b) there was obtained from 2-(2-methoxy-benzoyl)-3-dimethylamino-acrylic acid ethyl ester and S-methylisothiourea sulfate followed by saponification 4-(2-methoxy-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid as a white foam.

Example 63

- 10 **4-(2-Methoxy-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 15 there was obtained from 4-(2-methoxy-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 3-chloroperbenzoic acid 4-(2-methoxy-phenyl)-2-

- 15 methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 548.1 ($M+H^+$).

Example 64

4-(2-Methoxy-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 20 In an analogous manner to that described in Example 16 there was obtained from 4-(2-methoxy-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazin 4-(2-methoxy-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 568.5 ($M+H^+$).

- 25 **Example 65**

(3R,5S)-2-(3,5-Dimethyl-piperazin-1-yl)-4-(2-methoxy-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 20 there was obtained from 4-(2-methoxy-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-

- 30 benzyl)-methyl-amide and cis-2,6-dimethylpiperazine (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(2-methoxy-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 582.2 ($M+H^+$).

Example 66**4-(2-Methoxy-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 19 there was obtained from 4-(2-methoxy-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and piperazine 4-(2-methoxy-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 554.2 ($M+H^+$).

Example 67**10 4-(2-Methoxy-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 18 there was obtained from 4-(2-methoxy-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and morpholin 4-(2-methoxy-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, m.p. 190.8 – 192.0°.

Example 68**4-(4-Fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

20 In an analogous manner to that described in Example 37 c) there was obtained from 4-(4-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 4-(4-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 503 (M^+).

25

Example 69**4-(4-Fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 15 there was obtained from 4-(4-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amine and 3-chloroperbenzoic acid 4-(4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 535 (M^+).

Example 70

4-(4-Fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- In an analogous manner to that described in Example 16 there was obtained from 4-(4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazin 4-(4-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 555 (M^+), which was treated with fumaric acid in the usual way to give 4-(4-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 144.5-145.5°.

Example 71

(3R,5S)-2-(3,5-Dimethyl-piperazin-1-yl)-4-(4-fluoro-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- In an analogous manner to that described in Example 20 there was obtained from 4-(4-fluor-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and cis-2,6-dimethylpiperazine (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(4-fluoro-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 570.2 ($M+H^+$), which was treated with fumaric acid in the usual way to give (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(4-fluoro-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:0.5), m.p. 220-223°.

Example 72

4-(4-Fluor-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- In an analogous manner to that described in Example 19 there was obtained from 4-(4-fluor-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and piperazine 4-(4-fluor-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 542.2 ($M+H^+$), which was treated with fumaric acid in the usual way to give 4-(4-fluoro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 155-158°C.

Example 73**4-(4-Fluor-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 18 there was obtained from 4-(4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and Morpholin 4-(4-fluor-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 543.2 ($M+H^+$).

Example 74**10 4-(2-Fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 37 c) there was obtained from 4-(2-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 4-(2-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white solid, m.p. 109.5-110°.

The 4-(2-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

In an analogous manner to that described in Example 37 a), b) there was obtained from 2-(2-fluoro-benzoyl)-3-dimethylamino-acrylic acid ethyl ester and S-methylisothiourea sulfate followed by saponification 4-(2-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid as a white foam.

Example 75**25 4-(2-Fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 15 there was obtained from 4-(2-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 3-chloroperbenzoic acid 4-(2-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 536.2 ($M+H^+$).

Example 76**4-(2-Fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 16 there was obtained from 4-(2-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazin 4-(2-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 556.1 ($M+H^+$).

Example 77

(3R,5S)-2-(3,5-Dimethyl-piperazin-1-yl)-4-(2-fluoro-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 20 there was obtained from 4-(2-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and cis-2,6-dimethylpiperazine (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(2-fluoro-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 570.2 ($M+H^+$).

Example 78

15 4-(4-Fluor-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 19 there was obtained from 4-(2-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and piperazine 4-(4-fluor-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 542.2 ($M+H^+$), which was treated with fumaric acid in the usual way to give 4-(2-fluoro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 124.8-125.1°.

Example 79

25 4-(2-Fluor-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 18 there was obtained from 4-(2-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and morpholin 4-(2-fluor-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 542 (M^+).

Example 80

4-(4-Fluoro-2-methyl-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 42 -

In an analogous manner to that described in Example 37 c) there was obtained from 4-(4-fluoro-2-methyl-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 4-(4-fluoro-2-methyl-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white solid, MS (EI): 517 (M^+).

The 4-(4-fluoro-2-methyl-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

In an analogous manner to that described in Example 37 a), b) there was obtained from 2-(4-fluoro-2-methyl-benzoyl)-3-dimethylamino-acrylic acid ethyl ester and S-
10 methylisothiourea sulfate followed by saponification 4-(4-fluoro-2-methyl-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid as a white foam.

Example 81

4-(4-Fluoro-2-methyl-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

15 In an analogous manner to that described in Example 15 there was obtained from 4-(4-fluoro-2-methyl-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 3-chloroperbenzoic acid 4-(4-fluoro-2-methyl-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 549 (M^+).

20 **Example 82**

4-(4-Fluoro-2-methyl-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 16 there was obtained from 4-(4-fluoro-2-methyl-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazin 4-(4-fluoro-2-methyl-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 570.2 ($M+H^+$), which was treated with fumaric acid in the usual way to give 4-(4-fluoro-2-methyl-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 185.0-186.5°.

30 **Example 83**

(3R,5S)-2-(3,5-Dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- In an analogous manner to that described in Example 20 there was obtained from 4-(4-fluor-2-methyl-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and cis-2,6-dimethylpiperazine (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 548.1 ($M+H^+$), which was treated with fumaric acid in the usual way to give (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:0.5), m.p. 228-230°.

Example 84

- 10 4-(4-Fluor-2-methyl-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide
 In an analogous manner to that described in Example 19 there was obtained from 4-(4-fluor-2-methyl-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and piperazine 4-(4-Fluor-2-methyl-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 556.1 ($M+H^+$), which was treated with fumaric acid in the usual way to give 4-(2-fluoro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 143-145°.

Example 85

- 20 4-(4-Fluoro-2-methyl-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide
 In an analogous manner to that described in Example 18 there was obtained from 4-(4-fluoro-2-methyl-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and morpholin 4-(4-fluoro-2-methyl-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 557.1 ($M+H^+$).

Example 86

- 2-Methylsulfanyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide
 30 In an analogous manner to that described in Example 37 c) there was obtained from 2-methylsulfanyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 2-methylsulfanyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (EI): 535 (M^+).

The 2-methylsulfanyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

- In an analogous manner to that described in Example 37 a), b) there was obtained from 3-dimethylamino-2-(naphthalene-1-carbonyl)-acrylic acid ethyl ester and S-5 methylisothiourea sulfate followed by saponification 2-methylsulfanyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid as a white foam.

Example 87

2-Methylsulfonyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 10 In an analogous manner to that described in Example 15 there was obtained from 2-methylsulfanyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 3-chloroperbenzoic acid 2-methylsulfonyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 568.1 ($M+H^+$).

15 **Example 88**

2-(4-Methyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 20 In an analogous manner to that described in Example 16 there was obtained from 2-methylsulfonyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazin 2-(4-methyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white solid, m.p. 170.6-170.9°.

Example 89

(3R,5S)-2-(3,5-Dimethyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid

- 25 **(3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

- 30 In an analogous manner to that described in Example 20 there was obtained from 2-methylsulfonyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and cis-2,6-dimethylpiperazine (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide a white foam, MS (ISP): 602.1 ($M+H^+$), which was treated with fumaric acid in the usual way to give (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:0.5), m.p. 247-249°.

Example 90

4-Naphthalen-1-yl-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 19 there was obtained from 2-methylsulfonyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and piperazine 4-naphthalen-1-yl-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 574.2 ($M+H^+$), which was treated with fumaric acid in the usual way to give 4-naphthalen-1-yl-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide fumarate (1:1), m.p. 176-178°.

Example 91

2-Morpholin-4-yl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 18 there was obtained from 2-methylsulfonyl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and morpholin 2-morpholin-4-yl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 575.1 ($M+H^+$).

Example 92

20 **4-Phenyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**

In an analogous manner to that described in Example 3 d) there was obtained from 4-phenyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 4-phenyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless solid, m.p. 127°-128°.

The 4-phenyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

In an analogous manner to that described in example 3 b) starting from 2-benzoyl-3-dimethylamino-acrylic acid ethyl ester and 3-amidinopyridine hydrochloride, followed by 30 saponification as described in example 3c) there was obtained 4-phenyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid, MS (EI): 277 (M^+).

Example 93

4-(2-Chloro-4-fluorophenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 37 c) there was obtained from 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid and (3,5-bis-trifluoromethyl-benzyl)-methyl-amine 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 538.1 (M+H⁺).

The 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid used as the starting substance was obtained as follows:

- In an analogous manner to that described in Example 37 a), b) there was obtained from 2-(2-chloro-4-fluoro-benzoyl)-3-dimethylamino-acrylic acid ethyl ester and S-10 methylisothiourea sulfate followed by saponification 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid as a white foam.

Example 94

4-(2-Chloro-4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 15 In an analogous manner to that described in Example 15 there was obtained from 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 3-chloroperbenzoic acid 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 570.1 (M+H⁺).

Example 95

4-(2-Chloro-4-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- In an analogous manner to that described in Example 16 there was obtained from 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 1-methylpiperazine 4-(2-chloro-4-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 590.1 (M+H⁺).

Example 96

4-(2-Chloro-4-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide

- 30 In an analogous manner to that described in Example 18 there was obtained from 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and morpholine 4-(2-chloro-4-fluoro-phenyl)-2-

morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 577.0 (M+H⁺).

Example 97

- 4-(2-Chloro-4-fluoro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**
- In an analogous manner to that described in Example 19 there was obtained from 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and piperazine 4-(2-chloro-4-fluoro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a white foam, MS (ISP): 576.0 (M+H⁺).

Example 98

- 4-(2-Chloro-4-fluoro-phenyl)-2-(2-dimethylamino-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**
- In an analogous manner to that described in Example 26 there was obtained from 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 2-dimethylamino-ethanol 4-(2-chloro-4-fluoro-phenyl)-2-(2-dimethylamino-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a colorless oil, MS (ISP): 579.1(M+H⁺).

Example 99

- 4-(2-Chloro-4-fluoro-phenyl)-2-(3-dimethylamino-propoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**
- In an analogous manner to that described in Example 27 there was obtained from 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and 2-dimethylamino-propanol 4-(2-chloro-4-fluoro-phenyl)-2-(3-dimethylamino-propoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amid as a colorless oil, MS (ISP): 593.1 (M+H⁺).

Example 100

- 4-(2-Chloro-4-fluoro-phenyl)-2-(2-morpholin-4-yl-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide**
- In an analogous manner to that described in Example 24 there was obtained from 4-(2-chloro-4-fluoro-phenyl)-2-methylsulfonyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and N-(2-hydroxyethyl)morpholine 4-(2-chloro-4-fluoro-phenyl)-2-(2-morpholin-4-yl-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide as a pale yellow oil, MS (ISP): 621.0 (M+H⁺).

Example 101

2-Methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide

To a solution of 3.00 g (11.52 mmol) 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid in 70 ml CH₂Cl₂ 3.21 ml (23.05 mmol) triethylamine, 1.55 g (11.52 mmol) 1-hydroxybenzotriazole and 2.20 g (11.52 mmol) N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride 2.29 g (12.68 mmol) (3,5-dimethoxy-benzyl)-methyl-amine were added. The reaction mixture was stirred for 16 hrs. The reaction mixture was diluted with 100 ml CH₂Cl₂, washed with 100 ml 0.5N HCl and 100 ml H₂O. The aqueous layers were backextracted with 100 ml CH₂Cl₂. The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH) to give 4.20 g (86 %) 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide as a colorless oil, MS (ISP): 424.1 (M+H⁺).

Example 102

15 **2-Methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide**

To a solution of 4.00 g (9.44 mmol) 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide in 100 ml CH₂Cl₂ 5.82 g (23.61 mmol) 3-chloroperbenzoic acid (70%) was added at 5° and the reaction mixture stirred for 3 hrs. at 20 RT. After addition of 100 ml sat. NaHCO₃-solution, the layers were separated, the organic phase washed with sat. NaHCO₃-solution, dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/ethyl acetate 4:1) to give 2.00 g (46 %) 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide as a colorless foam, MS (ISP): 456.5 (M+H⁺).

Example 103

25 **2-(4-Methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide**

In an analogous manner to that described in Example 16 there was obtained from 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide and 1-methylpiperazine 2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide as a colorless oil, MS (ISP): 476.3 (M+H⁺).

Example 104

2-Morpholin-4-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide

- In an analogous manner to that described in Example 18 there was obtained from 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide and morpholine 2-morpholin-4-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide as a colorless foam, MS (ISP): 463.3 ($M+H^+$).

Example 105

2-(2-Dimethylamino-ethylamino)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide

- In an analogous manner to that described in Example 21 there was obtained from 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide and 2-dimethylaminoethylamine 2-(2-dimethylamino-ethylamino)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide as a pale yellow oil, MS (ISP): 464.4 ($M+H^+$).

Example 106

2-(2-Dimethylamino-ethoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide

- In an analogous manner to that described in Example 26 there was obtained from 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide and 2-dimethylaminoethanol 2-(2-dimethylamino-ethoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethoxy-benzyl)-methyl-amide as a pale yellow oil, MS (EI): 465.3 ($M+H^+$).

Example 107

25 2-Methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide

To a solution of 2.60 g (9.99 mmol) 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid in 70 ml CH_2Cl_2 2.78 ml (19.98 mmol) triethylamine, 1.34 g (9.99 mmol) 1-hydroxybenzotriazole and 1.91 g (9.99 mmol) N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride 1.78 g (11.99 mmol) (3,5-dimethoxy-benzyl)-methyl-

- 30 amine were added. The reaction mixture was stirred for 16 hrs. The reaction mixture was diluted with 100 ml CH_2Cl_2 , washed with 100 ml 0.5N HCl and 100 ml H_2O . The aqueous layers were backextracted with 100 ml CH_2Cl_2 . The combined organic layers were dried ($MgSO_4$), filtered and evaporated. The residue was purified by chromatography (SiO_2 ,

$\text{CH}_2\text{Cl}_2/\text{MeOH}$ 40:1) to give 3.20 g (82 %) 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide as a pale yellow oil, MS (EI): 391 (M^+).

Example 108

- 5 2-Methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide

To a solution of 3.20 g (8.17 mmol) 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide in 70 ml CH_2Cl_2 3.52 g (20.43 mmol) 3-chloroperbenzoic acid (70%) was added at 5° and the reaction mixture stirred for 3 hrs. at 10 RT. After addition of 100 ml sat. NaHCO_3 -solution, the layers were separated, the organic phase washed with sat. NaHCO_3 -solution, dried (Na_2SO_4), filtered and evaporated. The residue was purified by chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{ethyl acetate}$ 4:1) to give 2.55 g (73 %) 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide as a colorless foam, MS (EI): 423 (M^+).

15 Example 109

- 2-(4-Methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 16 there was obtained from 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-

- 20 amide and 1-methylpiperazine 2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide as a colorless foam, MS (ISP): 444.5 ($\text{M}+\text{H}^+$).

Example 110

- 25 2-Morpholin-4-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 18 there was obtained from 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide and morpholine 2-morpholin-4-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide as a colorless foam, MS (EI): 430 (M^+).

30 Example 111

- 2-(2-Dimethylamino-ethoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide

In an analogous manner to that described in Example 26 there was obtained from 2-methanesulfonyl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-

amide and 2-dimethylaminoethanol 2-(2-dimethylamino-ethoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide as a pale yellow oil, MS (ISP): 433.5 ($M+H^+$).

Example 112

5 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-isobutyramide

a) (2-Methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-carbamic acid tert.-butyl ester

To a solution of 2.33 g (8.95 mmol) 2-methylsulfanyl-4-o-tolyl-pyrimidine-5-carboxylic acid, 1.25 ml triethylamine (8.95 mmol) and 1.68 ml (17.9 mmol) t-butanol in 30 ml THF, 10 1.97 ml (8.95 mmol) diphenylphosphorylazide were added and the resulting solution heated at reflux for 12 hrs. After evaporation of the solvent, the residue was distributed between CH_2Cl_2 and H_2O . The aqueous phase was extracted twice with CH_2Cl_2 . The combined organic layers were dried (Na_2SO_4), filtered and evaporated. The residue was purified by chromatography (SiO_2 , CH_2Cl_2 /ethyl acetate 15:1) to give 1.95 g (65%) (2- 15 methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-carbamic acid tert.-butyl ester as a colorless solid, MS (TSP): 331 (M^+).

b) Methyl-(2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-carbamic acid tert.-butyl ester

To a solution of 1.9 g (5.73 mmol) (2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-carbamic acid tert.-butyl ester in 15 ml N,N-dimethylformamide 0.29 g (7.45 mmol) sodiumhydride (60% dispersion in mineraloil) was added and the reaction mixture stirred for 1 hr. After the addition of 0.57ml (9.17 mmol) methyl iodide at 0°, the reaction mixture was stirred for 3 hrs. The reaction mixture was distributed between 75 ml H_2O , 75 ml brine and 75 ml CH_2Cl_2 . The phases were separated, the aqueous layer washed twice with 75 ml CH_2Cl_2 . The combined organic layers were dried (Na_2SO_4), filtered and evaporated. The residue 25 was purified by chromatography (SiO_2 , CH_2Cl_2 /ethyl acetate 15:1) to give 1.95 g (98 %) methyl-(2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-carbamic acid tert.-butyl ester as a colorless oil. MS (TSP): 345 (M^+).

c) Methyl-(2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-amine

A solution of 1.95 g (5.64 mmol) methyl-(2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)- 30 carbamic acid tert-butyl ester in 30 ml MeOH/HCl (2N) was stirred at 50° for 3 hr. After evaporation of the solvent, the residue was distributed between 40 ml 1N NaOH and 40 ml CH_2Cl_2 . The phases were separated, the aqueous layer washed twice with 50 ml CH_2Cl_2 . The combined organic layers were dried (Na_2SO_4), filtered and evaporated. The residue

was purified by chromatography (SiO_2 , CH_2Cl_2 /ethyl acetate 10:1) to give 1.30 g (94 %) methyl-(2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-amine as a white solid, MS (EI): 245 (M^+).

d) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-methylsulfanyl-4-o-tolyl-

pyrimidin-5-yl)-isobutyramide

To a solution of 1.30 g (5.3 mmol) methyl-(2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-amine and 1.36 ml (7.95 mmol) N-ethyldiisopropylamine in 15 ml CH_2Cl_2 a solution of 1.30 g (5.3 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride in 5 ml CH_2Cl_2 were added and the reaction mixture stirred for 24 hrs. at RT. The reaction mixture was poured onto 50 ml 0.5 N NaOH-solution. The phases were separated, the aqueous layer washed twice with 50 ml CH_2Cl_2 . The combined organic layers were dried (Na_2SO_4), filtered and evaporated. The residue was purified by chromatography (SiO_2 , CH_2Cl_2 /ethyl acetate 10:1) to give 2.30 g (82 %) 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(2-methylsulfanyl-4-o-tolyl-pyrimidin-5-yl)-isobutyramide as a white solid, m.p. 124-125°, MS (ISP): 528.2 ($\text{M}+\text{H}^+$).

Example 113

2-(3,5-Bis-trifluoromethyl-phenyl)-N-(2-methanesulfonyl-4-o-tolyl-pyrimidin-5-yl)-N-methyl-isobutyramide

To a solution of 2.20 g (4.17 mmol) 2-methylsulfanyl-4-phenyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide in 50 ml CH_2Cl_2 2.57 g (10.43 mmol) 3-chloroperbenzoic acid (70%) was added at 5° and the reaction mixture stirred for 3 hrs. at RT. After addition of 100 ml sat. NaHCO_3 -solution, the layers were separated, the organic phase washed with sat. NaHCO_3 -solution, dried (Na_2SO_4), filtered and evaporated. The residue was purified by chromatography (SiO_2 , CH_2Cl_2 /ethyl acetate 10:1) to give 2.30 g (98 %) 2-(3,5-bis-trifluoromethyl-phenyl)-N-(2-methanesulfonyl-4-o-tolyl-pyrimidin-5-yl)-N-methyl-isobutyramide as a colorless foam, MS (ISP): 560.2 ($\text{M}+\text{H}^+$).

Example 114

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidin-5-yl]-isobutyramide

To a solution of 0.5 g (0.89 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-(2-methanesulfonyl-4-o-tolyl-pyrimidin-5-yl)-N-methyl-isobutyramide in 10 ml dioxane 0.25 ml (2.23 mmol) 1-methylpiperazine was added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH_2Cl_2 and 50 ml H_2O . The aqueous layer was extracted with 50 ml CH_2Cl_2 , the combined organic layers dried (MgSO_4), filtered and evaporated. The residue was purified by

chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 110:10:1) to give 0.37 g (71 %) 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidin-5-yl]-isobutyramide as a colorless solid, m.p. 149°-151°, MS (ISP): 580.1 (M+H⁺).

Example 115

- 5 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-morpholin-4-yl-4-o-tolyl-pyrimidin-5-yl)-isobutyramide
To a solution of 0.4 g (0.71 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-(2-methanesulfonyl-4-o-tolyl-pyrimidin-5-yl)-N-methyl-isobutyramide in 10 ml dioxane 0.19 ml (2.14 mmol) morpholine was added. The reaction mixture was stirred for 16 hrs.
- 10 After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/ethyl acetate) to give 0.34 g (84 %) 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(2-morpholin-4-yl-4-o-tolyl-pyrimidin-5-yl)-isobutyramide as a colorless solid, m.p. 151°-152°, MS (ISP): 567.1 (M+H⁺).

Example 116

2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(2-dimethylamino-ethylamino)-4-o-tolyl-pyrimidin-5-yl]-N-methyl-isobutyramide

- To a solution of 0.35 g (0.63 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-(2-methanesulfonyl-4-o-tolyl-pyrimidin-5-yl)-N-methyl-isobutyramide in 10 ml dioxane 0.20 ml (1.88 mmol) 2-dimethylaminoethylamine was added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 50 ml CH₂Cl₂ and 50 ml H₂O. The aqueous layer was extracted with 50 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH) to give 0.23 g (64 %) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-(2-dimethylamino-ethylamino)-4-o-tolyl-pyrimidin-5-yl]-N-methyl-isobutyramide as a colorless solid, m.p. 143°-144°, MS (ISP): 568.3 (M+H⁺).

Example 117

2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(2-dimethylamino-ethoxy)-4-o-tolyl-pyrimidin-

- 30 5-yl]-N-methyl-isobutyramide
To a solution of 0.4 g (0.71 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-(2-methanesulfonyl-4-o-tolyl-pyrimidin-5-yl)-N-methyl-isobutyramide in 15 ml acetonitrile 0.09 ml (0.93 mmol) 2-dimethylamino-ethanol and 1.17 g (3.57 mmol) Cs₂CO₃ were added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the

residue was distributed between 40 ml CH₂Cl₂ and 40 ml H₂O. The aqueous layer was extracted with 40 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 110:10:1) to give 0.36 g (88 %) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-(2-dimethylamino-ethoxy)-4-o-tolyl-pyrimidin-5-yl]-N-methyl-isobutyramide as a colorless solid, m.p. 140°-141°, MS (ISP): 569.2 (M+H)⁺.

Example 118

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(2-morpholin-4-yl-ethoxy)-4-o-tolyl-pyrimidin-5-yl]-isobutyramide

- 10 To a solution of 0.4 g (0.71 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-(2-methanesulfonyl-4-o-tolyl-pyrimidin-5-yl)-N-methyl-isobutyramide in 15 ml acetonitrile 0.12 g (0.93 mmol) N-(2-hydroxymethyl)-morpholine and 1.17 g (3.57 mmol) Cs₂CO₃ were added. The reaction mixture was stirred for 16 hrs. After evaporation of the solvent, the residue was distributed between 40 ml CH₂Cl₂ and 40 ml H₂O. The aqueous layer was
 15 extracted with 40 ml CH₂Cl₂, the combined organic layers dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂/MeOH/NH₄OH 110:10:1) to give 0.35 g (80 %) 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(2-morpholin-4-yl-ethoxy)-4-o-tolyl-pyrimidin-5-yl]-isobutyramide as a colorless foarn, MS (ISP): 611.1 (M+H⁺).

20

Example A

Tablets of the following composition are manufactured in the usual manner:

mg/tablet

Active substance	5
25 Lactose	45
Corn starch	15
Microcrystalline cellulose	34
Magnesium stearate	1
Tablet weight	100

30

Example B

Capsules of the following composition are manufactured:

mg/capsule

Active substance	10
5 Lactose	155
Corn starch	30
Talc	5
Capsule fill weight	200

- The active substance, lactose and corn starch are firstly mixed in a mixer and then in
 10 a comminuting machine. The mixture is returned to the mixer, the talc is added thereto
 and mixed thoroughly. The mixture is filled by machine into hard gelatine capsules.

Example C

Suppositories of the following composition are manufactured:


mg/supp.

15 Active substance	15
Suppository mass	1285
Total	1300

- The suppository mass is melted in a glass or steel vessel, mixed thoroughly and
 cooled to 45°C. Thereupon, the finely powdered active substance is added thereto and
 20 stirred until it has dispersed completely. The mixture is poured into suppository moulds of
 suitable size, left to cool, the suppositories are then removed from the moulds and packed
 individually in wax paper or metal foil.

Claims

1. Compounds of the general formula



wherein

- 5 R¹ is hydrogen or halogen;
- R² is hydrogen, halogen, lower alkyl or lower alkoxy;
- R¹ and R² may be together with the two carbon ring atoms -CH=CH-CH=CH-;
- R³ is halogen, trifluoromethyl, lower alkyl or lower alkoxy;
- R⁴/R^{4'} are independently from each other hydrogen or lower alkyl;
- 10 R⁵ is lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, -(CH₂)_n-piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, -(CH₂)_n-morpholinyl, -(CH₂)_n-piperidinyl, -(CH₂)_{n+1}-imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH₂)_{n+1}N(R^{4''})₂, -(CH₂)_{n+1}N(R^{4''})₂, -O-(CH₂)_{n+1}-morpholinyl, -O-(CH₂)_{n+1}-piperidinyl or -O-(CH₂)_{n+1}N(R^{4''})₂, wherein R^{4''} is hydrogen or lower alkyl; and
- 15 n is 0 - 2;
- X is -C(O)N(R^{4''})- or -N(R^{4''})C(O)-;

and pharmaceutically acceptable acid addition salts thereof.

- 20 2. A compound according to claim 1, wherein X is -C(O)N(R^{4''})-, R^{4''} is methyl and R⁵ is piperazinyl, optionally substituted by one or two methyl groups.
- 3. A compound according to claim 2, which is

- 4-(2-bromo-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
(3R,5S)-4-(2-bromo-phenyl)-2-(3,5-dimethyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
5 4-(2-bromo-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-chloro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
(3R,5S)-4-(2-chloro-phenyl)-2-(3,5-dimethyl-piperazin-1-yl)-pyrimidine-5-carboxylic
10 acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-chloro-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
15 (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
2-piperazin-1-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-methoxy-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
20 (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(2-methoxy-phenyl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-methoxy-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
25 4-(4-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-fluoro-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
(3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(2-fluoro-phenyl)-pyrimidine-5-carboxylic
30 acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(4-fluor-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(4-fluoro-2-methyl-phenyl)-2-(4-methyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid
(3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
35 (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyrimidine-5-
carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,

- 4-(4-fluor-2-methyl-phenyl)-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
2-(4-methyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
5 (3R,5S)-2-(3,5-dimethyl-piperazin-1-yl)-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and
4-naphthalen-1-yl-2-piperazin-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide.

4. A compound according to claim 1, in which X is $-C(O)N(R^4)$ -, R⁴ is methyl and
10 R⁵ is morpholinyl or $-O(CH_2)_2$ -morpholinyl .

5. A compound according to claim 4, which is

- 4-(2-bromo-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(2-chloro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
15 4-(2-chloro-phenyl)-2-(2-morpholin-4-yl-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
2-morpholin-4-yl-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
20 4-(2-methoxy-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
4-(4-fluoro-2-methyl-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide and
25 2-morpholin-4-yl-4-naphthalen-1-yl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide.

6. A compound according to claim 1, in which X is $-C(O)N(R^4)$ -, R⁴ is methyl and
R⁵ is $-NH(CH_2)_2N(CH_3)_2$, $-O(CH_2)_2N(CH_3)_2$ or $-O(CH_2)_3N(CH_3)_2$.

30 7. A compound according to claim 6, which is

- 4-(2-chloro-phenyl)-2-(2-dimethylamino-ethylamino)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide
4-(2-chloro-phenyl)-2-(2-dimethylamino-ethoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,

- 59 -

- 4-(2-chloro-phenyl)-2-(3-dimethylamino-propoxy)-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide,
 2-(2-dimethylamino-ethoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide or
 5 2-(3-dimethylamino-propoxy)-4-o-tolyl-pyrimidine-5-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide.

8. A compound according to claim 1, in which X is $-N(R^4)C(O)-$, R^4 is methyl and R^5 is morpholinyl or piperazinyl, optionally substituted by lowre alkyl.

10 9. A compound according to claim 8, which is

2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyrimidin-5-yl]-isobutyramide and
 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(2-morpholin-4-yl-4-o-tolyl-pyrimidin-5-yl)-isobutyramide.


15

10. A medicament containing one or more compounds as claimed in any one of claims 1-9 and pharmaceutically acceptable excipients.


11. A medicament according to claim 10 for the treatment of diseases related to the NK-1 receptor antagonists.

20 12. A process for preparing a compound of formula I as defined in claim 1, which process comprises

a) reacting a compound of formula




with a compound of formula



25


to a compound of formula




wherein R¹-R⁵ and n have the significances given in claim 1,

or


- 5 b) reacting a compound of formula



with a compound of formula



to give a compound of formula



10

wherein R¹-R⁵ and n have the significances given in claim 1, or

- c) modifying one or more substituents R¹-R⁵ within the definitions given above, and

if desired, converting the compound obtained into a pharmaceutically acceptable acid addition salt.

- 61 -

13. A compound according to any one of claims 1-9, whenever prepared by a process as claimed in claim 12 or by an equivalent method.

14. The use of a compound of formula I in any one of claims 1-9 for the treatment of diseases.

5 15. The use of a compound of formula I in any one of claims 1-9 for the manufacture of a medicament containing one or more compounds of formula I for the treatment of diseases related to the NK-1 receptor.

16. The invention as hereinbefore described.

10

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/04701

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7 C07D239/42 C07D239/48 C07D239/34 C07D239/38 C07D239/28 C07D401/04 A61K31/505 A61P29/00					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
IPC 7 C07D A61K A61P					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)					
CHEM ABS Data					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
A	WO 97 09315 A (SIGNAL PHARMACEUTICALS) 13 March 1997 (1997-03-13) claims; example 43 -----				1,2, 10-15
A	EP 0 169 712 A (FUJISAWA) 29 January 1986 (1986-01-29) claims -----				1,2, 10-15
<input type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.			
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed					
T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *8* document member of the same patent family					
Date of the actual completion of the international search			Date of mailing of the international search report		
31 October 2000			08/11/2000		
Name and mailing address of the ISA			Authorized officer		
European Patent Office, P.B. 5818 Patentstaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016			Francois, J		

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatir	Application No
	PCT/EP 00/04701

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9709315	A 13-03-1997	US 5811428 A			22-09-1998
		AU 7013096 A			27-03-1997
		AU 7163196 A			27-03-1997
		CA 2230894 A			13-03-1997
		CA 2230896 A			13-03-1997
		EP 0850228 A			01-07-1998
		JP 11512390 T			26-10-1999
		JP 11512399 T			26-10-1999
		WO 9709325 A			13-03-1997
		US 5935966 A			10-08-1999
EP 169712	A 29-01-1986	AT 59034 T			15-12-1990
		AU 4520285 A			23-01-1986
		DE 3580875 D			24-01-1991
		DK 327985 A			20-01-1986
		ES 545347 D			16-10-1986
		ES 8700661 A			16-01-1987
		FI 852796 A			20-01-1986
		GR 851735 A			26-11-1985
		JP 1918770 C			07-04-1995
		JP 6049688 B			29-06-1994
		JP 61040272 A			26-02-1986
		NO 852869 A			20-01-1986
		US 4698340 A			06-10-1987
		ZA 8505369 A			25-06-1986
		AT 58897 T			15-12-1990
		AU 4814385 A			10-04-1986
		DE 3580823 D			17-01-1991
		DK 443685 A			02-04-1986
		EP 0177287 A			09-04-1986
		ES 547419 D			16-03-1987
		ES 8704153 A			01-06-1987
		FI 853698 A			02-04-1986
		GR 852369 A			20-12-1985
		JP 61087669 A			06-05-1986
		NO 853853 A			02-04-1986
		US 4727073 A			23-02-1988
		ZA 8507359 A			28-05-1986

Form PCT/ISA/210 (patent family annex) (July 1992)